There isn’t one single new pill for lung cancer. Several oral medications have been approved in recent years, each designed to target a specific genetic mutation driving the cancer’s growth. The most notable recent approvals include zongertinib (for HER2-mutated tumors), lazertinib (for EGFR-mutated tumors), and repotrectinib (for ROS1-positive tumors). Which pill applies to you depends entirely on the genetic profile of your tumor, which is why biomarker testing has become a critical first step before any treatment decision.
How These Pills Work
Lung cancer, particularly a type called non-small cell lung cancer (NSCLC), is often driven by specific gene mutations that act like a stuck “on” switch, telling cancer cells to keep growing. Targeted oral therapies are designed to block that switch. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, these pills zero in on the exact protein or pathway fueling a particular tumor. That precision generally means fewer side effects and, in many cases, better outcomes.
The mutations these drugs target have names you may see on test results or hear from your oncologist: EGFR, ALK, ROS1, HER2, and KRAS G12C are among the most common. Each mutation requires a different drug, which is why no single pill works for all lung cancers.
Zongertinib: For HER2-Mutated Tumors
Zongertinib (brand name Hernexeos) received accelerated FDA approval in February 2026 for adults with advanced non-squamous NSCLC whose tumors carry a specific type of HER2 mutation. HER2 mutations are found in roughly 2% to 4% of NSCLC cases. Before zongertinib, patients with this mutation had limited targeted options and often relied on broader chemotherapy regimens. The drug is made by Boehringer Ingelheim and works by blocking the overactive signaling caused by the HER2 mutation.
Lazertinib: A New EGFR Combination
EGFR mutations are among the most common drivers of NSCLC, especially in people who have never smoked. In August 2024, the FDA approved lazertinib (brand name Lazcluze) for use alongside an infused medication called amivantamab as a first-line treatment for advanced NSCLC with specific EGFR mutations (exon 19 deletions or exon 21 L858R substitutions). The lazertinib portion is a once-daily pill taken at 240 mg, with or without food. The combination approach attacks the cancer through two different mechanisms at once, aiming to improve on what earlier single-drug treatments could achieve.
Osimertinib: Updated Survival Data
Osimertinib (brand name Tagrisso) isn’t brand-new, but updated long-term data has reinforced its role as a cornerstone treatment. Originally approved for advanced EGFR-mutated NSCLC, it’s now also used after surgery to reduce the risk of cancer coming back. In the ADAURA trial, published in the New England Journal of Medicine, 88% of patients who took osimertinib after surgery were alive at five years, compared with 78% who received a placebo. For patients with more advanced stage II to IIIA disease, the five-year survival rate was 85% with osimertinib versus 73% without it. Those numbers represent a meaningful shift in how early-stage, surgically removed lung cancer is managed.
Repotrectinib: For ROS1-Positive Cancers
ROS1 gene fusions occur in about 1% to 2% of NSCLC cases. The FDA approved repotrectinib (brand name Augtyro) for ROS1-positive NSCLC, and its performance varies based on whether the patient has received a prior ROS1-targeting drug. In patients who hadn’t been treated with a ROS1 inhibitor before, 79% saw their tumors shrink, and the typical response lasted over 34 months. For patients who had already tried a ROS1 inhibitor, the response rate was 38% with a median duration of about 15 months. That second number matters because ROS1-positive cancers often develop resistance to first-line drugs, and having a second effective option is significant.
Alectinib After Surgery for ALK-Positive Cancers
ALK gene rearrangements drive about 5% of NSCLC cases. Alectinib (brand name Alecensa) has been used for advanced ALK-positive lung cancer for years, but a major trial published in the New England Journal of Medicine tested it in a new role: as a treatment given after surgery to prevent recurrence. The results were striking. Among patients with stage II or IIIA disease, 93.8% of those taking alectinib were alive and cancer-free at two years, compared with just 63% of those who received standard chemotherapy. That roughly 30-percentage-point gap has made alectinib a leading option for patients whose early-stage ALK-positive tumors have been surgically removed.
KRAS G12C Inhibitors
KRAS mutations were long considered “undruggable” because the protein’s structure was so difficult to target. That changed with the approval of adagrasib (brand name Krazati), which received accelerated FDA approval in December 2022 for previously treated KRAS G12C-mutated NSCLC. Another drug in this class, sotorasib, was approved earlier. These pills represent a breakthrough for a mutation found in roughly 13% of NSCLC adenocarcinomas. In broader studies of heavily pretreated patients with various KRAS G12C-mutated solid tumors, adagrasib produced tumor shrinkage in about 35% of patients, with a median overall survival of 14 months, notable given that most of these patients had already failed two or more prior treatments.
Biomarker Testing Comes First
None of these pills can be prescribed without first identifying the specific mutation in your tumor. This process, called biomarker testing, typically involves analyzing a tissue biopsy or sometimes a blood sample. The test looks for genetic alterations like EGFR mutations, ALK rearrangements, ROS1 fusions, HER2 mutations, and KRAS G12C mutations, among others. Results usually take one to two weeks. If your oncologist hasn’t mentioned biomarker testing, it’s worth asking, because the right oral therapy can only be matched to the right patient through this step. Current guidelines recommend comprehensive biomarker testing for all patients with non-squamous NSCLC regardless of stage.
What Side Effects to Expect
Targeted pills are generally easier to tolerate than traditional chemotherapy, but they aren’t side-effect-free. The specific side effects depend on which pathway the drug blocks. Drugs that target the EGFR pathway commonly cause skin rash, diarrhea, fatigue, loss of appetite, nail splitting or changes, eye irritation, and unusual eyelash growth. These effects range from mild nuisances to problems severe enough to require a dose reduction. In clinical studies of EGFR-targeting pills, some patients needed lower doses to manage side effects while staying on treatment.
One practical detail that matters more than many patients realize: whether you take these pills with food or on an empty stomach can change how much drug your body absorbs by five- to ten-fold. Always follow the specific instructions for your medication. Some are taken with food, others without, and getting this wrong can meaningfully affect how well the drug works or how intense the side effects are.
Why There Are So Many Options Now
Lung cancer used to be treated as a single disease. Today, it’s understood as a collection of diseases defined by their molecular drivers. A tumor with an EGFR mutation behaves differently, and responds to different treatments, than one with an ALK rearrangement or a KRAS G12C mutation. This shift toward precision medicine explains why there’s no single “new pill for lung cancer” but rather a growing toolkit of oral drugs, each matched to a specific biological target. The pace of approvals has accelerated significantly, with new drugs and new uses for existing drugs reaching patients every year.